M Alkema, M J Smit, C Marin-Mogollon, K Totté, K Teelen, G J van Gemert, M van de Vegte-Bolmer, B G Mordmüller, J M Reimer, K L Lövgren-Bengtsson, R W Sauerwein, T Bousema, J Plieskatt, M Theisen, M M Jore, M B B McCall
BACKGROUND: The stalling global progress in malaria control highlights the need for novel tools for malaria elimination, including transmission-blocking vaccines. Transmission-blocking vaccines aim to induce human antibodies that block parasite development in the mosquito and mosquitoes becoming infectious. The Pfs48/45 protein is a leading Plasmodium falciparum transmission-blocking vaccine candidate. The R0.6C fusion protein, consisting of Pfs48/45 domain 3 (6C) and the N-terminal region of P...
April 23, 2024: BMC Medicine